Rockwell Medical Q3 net sales fall steeper-than-expected 44% as largest customer leaves

Rockwell Medical

12/11/2025 11:08

Overview

Rockwell Medical Q3 net sales fell 44% yr/yr, missing analyst expectations

Company achieved profitability on an adjusted EBITDA basis for Q3 2025

Rockwell Medical's cash position increased to $23.7 mln at September 30, 2025

Outlook

Rockwell Medical reiterates 2025 net sales guidance of $65 mln to $70 mln

Company expects 2025 gross margin between 16% and 18%

Rockwell Medical projects 2025 adjusted EBITDA between ($0.5) mln and $0.5 mln

Result Drivers

CUSTOMER LOSS - Net sales decreased due to largest customer transitioning to another supplier

NEW AGREEMENTS - Co signed new long-term product purchasing agreements with medical centers and hospital systems

OPERATIONAL EFFICIENCY - Co focused on right-sizing organization to enhance operational efficiency and support growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Miss
$15.93 mln
$16.20 mln (2 Analysts)
Q3 EPS
-$0.05
Q3 Net Income
-$1.75 mln
Q3 Gross Profit
$2.27 mln
Q3 Operating Income
-$1.58 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Rockwell Medical Inc is $4.00, about 73.8% above its November 11 closing price of $1.05

Press Release: ID:nBw2ygMNSa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)